Skye Bioscience Inc (FRA:09R)

Q3 2025 Skye Bioscience Inc Earnings Call Transcript

Nov 10, 2025 / 09:30 PM GMT

Release Date Price: €1.13 (-0.88%)

Transcript 8-K10-Q

Key Points

Positve

Skye Bioscience Inc (SKYE) ended the third quarter with $35.3 million in cash and cash equivalents, expected to fund operations into 2027.
The company reported promising results from its phase 2A study, showing synergistic efficacy of nemasimab plus semaglutide, achieving approximately 3% additional weight loss compared to semaglutide alone.
The combination of nemasimab and semaglutide improved lean to fat mass ratio and reduced waist circumference, indicating a quality weight loss.
No neuropsychiatric signals or additive gastrointestinal burdens were observed, suggesting a favorable safety profile for nemasimab.
Skye Bioscience Inc (SKYE) is advancing its manufacturing and CMC work, focusing on scalability and reducing costs, which aligns with their target product profile.

Negative

R&D expenses increased significantly to $9.4 million from $4.9 million in the same period in 2024, primarily due to contract manufacturing and clinical trial costs.
The net loss for the quarter was $12.8 million, a substantial increase from $3.9 million in the same period in 2024.
The 26-week extension study enrolled only 43 patients, raising concerns about the statistical significance of the insights that can be drawn.
There is uncertainty regarding the optimal dosing for nemasimab, as the current doses did not achieve the expected efficacy.
The company faces challenges in ensuring compliance and retention in clinical trials, which could impact the reliability of the data.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SKYE.OQ - Skye Bioscience Inc
Q3 2025 Skye Bioscience Inc Earnings Call
Nov 10, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by. My name is Jordan and I'll be your conference operator today. At this time, I would like to welcome everyone to the Sky Bioscience 3rd quarter 2025 financial results and business update call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. I would now like to turn the conference over to Bernie Hertel, head of investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hello, and thank you all for participating in today

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.